154 related articles for article (PubMed ID: 21883030)
1. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
Minarik J; Scudla V; Tichy T; Pika T; Bacovsky J; Lochman P; Zadrazil J
Leuk Lymphoma; 2012 Feb; 53(2):330-1. PubMed ID: 21883030
[No Abstract] [Full Text] [Related]
2. Managing light chain deposition disease.
Gertz MA
Leuk Lymphoma; 2012 Feb; 53(2):183-4. PubMed ID: 21913808
[No Abstract] [Full Text] [Related]
3. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T
Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
[No Abstract] [Full Text] [Related]
4. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
Szturz P; Adam Z; Vašků V; Feit J; Krejčí M; Pour L; Hájek R; Mayer J
Leuk Lymphoma; 2013 Jun; 54(6):1324-6. PubMed ID: 23061634
[No Abstract] [Full Text] [Related]
5. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.
Gharwan H; Truica CI
Med Oncol; 2012 Jun; 29(2):1197-201. PubMed ID: 21479696
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
Yuan ZG; Dun XY; Li YH; Hou J
J Hematol Oncol; 2009 Apr; 2():19. PubMed ID: 19400935
[TBL] [Abstract][Full Text] [Related]
8. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Tanaka T; Yamasaki R; Omura H; Hino N
Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
[No Abstract] [Full Text] [Related]
9. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
Khan AA; Siraj F; Bhargava M; Aggarwal S
BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23264156
[TBL] [Abstract][Full Text] [Related]
11. Drug pricing: No cure, no cost.
Jack A
BMJ; 2007 Jul; 335(7611):122-3. PubMed ID: 17641343
[TBL] [Abstract][Full Text] [Related]
12. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695
[TBL] [Abstract][Full Text] [Related]
13. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
14. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
Wondergem MJ; Grünberg K; Wittgen BP; Sonneveld P; Zweegman S
Histopathology; 2009 Apr; 54(5):631-3. PubMed ID: 19302537
[No Abstract] [Full Text] [Related]
15. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
[No Abstract] [Full Text] [Related]
16. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Wang HH; Tsui J; Wang XY; Liu SS; Li J
Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
[No Abstract] [Full Text] [Related]
17. Renal improvement in myeloma with bortezomib plus plasma exchange.
Burnette BL; Leung N; Rajkumar SV
N Engl J Med; 2011 Jun; 364(24):2365-6. PubMed ID: 21675906
[No Abstract] [Full Text] [Related]
18. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
[TBL] [Abstract][Full Text] [Related]
19. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
[No Abstract] [Full Text] [Related]
20. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
